Mail

UK Markets closed

FTSE 100
7,623.18
+58.91(+0.78%)
FTSE 250
18,892.71
+259.90(+1.39%)
AIM
806.77
+10.57(+1.33%)
GBP/EUR
1.1348
-0.0007(-0.06%)
GBP/USD
1.2371
+0.0059(+0.4763%)
BTC-GBP
22,908.71
-87.25(-0.38%)

Homes with secrets and hidden surprises

All of these properties have a little extra something that you don't normally find in a home

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Add to watchlist

0.6649

-0.0351

(-5.01%)

As of 11:41AM EDT. Market open.

Currency in USD

Valuation measures⁴

Market cap (intra-day)	N/A
Enterprise value	N/A
Trailing P/E	N/A
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	N/A
Price/book (mrq)	N/A
Enterprise value/revenue	N/A
Enterprise value/EBITDA	N/A

Trading information

Stock price history

Beta (5Y monthly)	1.03
52-week change ³	N/A
S&P500 52-week change ³	N/A
52-week high ³	1.5200
52-week low ³	0.4400
50-day moving average ³	0.7176
200-day moving average ³	0.7527

Share statistics

Avg vol (3-month) ³	432.2k
Avg vol (10-day) ³	604.78k
Shares outstanding ⁵	25.23M
Implied shares outstanding ⁶	N/A
Float ⁸	17.15M
% held by insiders ¹	25.44%
% held by institutions ¹	23.06%
Shares short (30 Jan 2023) ⁴	301.89k
Short ratio (30 Jan 2023) ⁴	0.53
Short % of float (30 Jan 2023) ⁴	1.33%
Short % of shares outstanding (30 Jan 2023) ⁴	1.08%
Shares short (prior month 29 Dec 2022) ⁴	189.78k

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	N/A
Trailing annual dividend yield ³	N/A
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	N/A
Ex-dividend date ⁴	N/A
Last split factor ²	N/A
Last split date ³	N/A

Financial highlights

Fiscal year

Fiscal year ends	30 Dec 2021
Most-recent quarter (mrq)	29 Sept 2022

Profitability

Profit margin	0.00%
Operating margin (ttm)	-30,468.63%

Management effectiveness

Return on assets (ttm)	-31.62%
Return on equity (ttm)	-55.10%

Income statement

Revenue (ttm)	61.82k
Revenue per share (ttm)	0.00
Quarterly revenue growth (yoy)	-97.80%
Gross profit (ttm)	-8.26M
EBITDA	N/A
Net income avi to common (ttm)	-18.82M
Diluted EPS (ttm)	-0.7840
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	26.53M
Total cash per share (mrq)	1.05
Total debt (mrq)	374.07k
Total debt/equity (mrq)	1.49
Current ratio (mrq)	8.71
Book value per share (mrq)	1.72

Cash flow statement

Operating cash flow (ttm)	-17.89M
Levered free cash flow (ttm)	-11.21M